PapersPMID:39267574
Inosine enhances the efficacy of immune-checkpoint inhibitors in advanced solid tumors: A randomized, controlled, Phase 2 study.
What moved
1 findingHow to read these marks →“Compared with the control group, the 6‐ and 12‐month PFS rates were significantly higher in the inosine group (Table 2).”
- Study
- RCT
- Dose studied
- inosine tablets, 0.2 g three times daily, added to PD-1/PD-L1 inhibitor regimen until progression or unacceptable toxicity
- Population
- Adults aged 18-75 with advanced (locally advanced, recurrent, metastatic or unresectable) malignant solid tumours receiving PD-1/PD-L1 inhibitor therapy, with or without targeted therapy or chemotherapy, in both arms; PFS rates at the 6- and 12-month landmarks
Study record
- Design
- randomised controlled trial
- Species
- human
- Population
- patients with advanced malignant solid tumors receiving PD-1/PD-L1 inhibitor therapy
- Participants
- 172
- Comparator
- no treatment
- Duration
- not reported
- Endpoints measured
- 74